Healthcare provider profile · identity verified

Rupika Uberoi-Nangia, MD

Internal Medicine · MEQUON, WI · NPI 1427165539

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	599	162
Atorvastatin Calcium	Atorvastatin Calcium	563	152
Levothyroxine Sodium	Levothyroxine Sodium	422	105
Rosuvastatin Calcium	Rosuvastatin Calcium	368	103
Losartan Potassium	Losartan Potassium	355	92
Omeprazole	Omeprazole	251	77
Alendronate Sodium	Alendronate Sodium	242	66
Metoprolol Succinate	Metoprolol Succinate	234	70
Gabapentin	Gabapentin	201	52
Pravastatin Sodium	Pravastatin Sodium	181	46
Lisinopril	Lisinopril	178	46
Hydrochlorothiazide	Hydrochlorothiazide	174	50
Simvastatin	Simvastatin	172	48
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	159	43
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	146	47
Metformin Hcl	Metformin Hcl	140	37
Pantoprazole Sodium	Pantoprazole Sodium	135	40
Escitalopram Oxalate	Escitalopram Oxalate	113	25
Sertraline Hcl	Sertraline Hcl	99	25
Eliquis	Apixaban	96	24
Zolpidem Tartrate	Zolpidem Tartrate	93	24
Metoprolol Tartrate	Metoprolol Tartrate	81	23
Mirtazapine	Mirtazapine	79	17
Allopurinol	Allopurinol	77	23
Duloxetine Hcl	Duloxetine Hcl	77	21
Furosemide	Furosemide	76	23
Jardiance	Empagliflozin	75	14
Synthroid	Levothyroxine Sodium	74	19
Meloxicam	Meloxicam	71	17
Clopidogrel	Clopidogrel Bisulfate	65	14
Metformin Hcl Er	Metformin Hcl	62	21
Tamsulosin Hcl	Tamsulosin Hcl	61	21
Glimepiride	Glimepiride	60	16
Carvedilol	Carvedilol	58	16
Paroxetine Hcl	Paroxetine Hcl	57	14
Tramadol Hcl	Tramadol Hcl	56	19
Donepezil Hcl	Donepezil Hcl	55	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	54	13
Potassium Chloride	Potassium Chloride	52	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	51	43
Fluticasone Propionate	Fluticasone Propionate	50	17
Montelukast Sodium	Montelukast Sodium	50	15
Spironolactone	Spironolactone	50	suppressed
Atenolol	Atenolol	49	15
Lorazepam	Lorazepam	45	12
Citalopram Hbr	Citalopram Hydrobromide	44	12
Estradiol	Estradiol	44	15
Trazodone Hcl	Trazodone Hcl	43	15
Alprazolam	Alprazolam	42	20
Celecoxib	Celecoxib	42	16
Fluoxetine Hcl	Fluoxetine Hcl	41	suppressed
Solifenacin Succinate	Solifenacin Succinate	40	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	40	suppressed
Nebivolol Hcl	Nebivolol Hcl	39	suppressed
Clonazepam	Clonazepam	35	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	34	suppressed
Famotidine	Famotidine	33	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	13
Albuterol Sulfate Hfa	Albuterol Sulfate	32	23
Valacyclovir	Valacyclovir Hcl	31	17
Xarelto	Rivaroxaban	31	suppressed
Bupropion Xl	Bupropion Hcl	30	suppressed
Pregabalin	Pregabalin	30	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	30	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Raloxifene Hcl	Raloxifene Hcl	29	suppressed
Arnuity Ellipta	Fluticasone Furoate	28	suppressed
Verapamil Er	Verapamil Hcl	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Glipizide Er	Glipizide	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Azithromycin	Azithromycin	23	23
Lansoprazole	Lansoprazole	21	suppressed
Memantine Hcl	Memantine Hcl	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Valsartan	Valsartan	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	11
Myrbetriq	Mirabegron	19	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Glipizide	Glipizide	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Memantine Hcl Er	Memantine Hcl	16	suppressed
Ozempic	Semaglutide	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Indapamide	Indapamide	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Methylprednisolone	Methylprednisolone	15	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Primidone	Primidone	14	suppressed
Temazepam	Temazepam	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Eszopiclone	Eszopiclone	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Baclofen	Baclofen	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error